Cardiff Oncology Inc(CRDF) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.59 | Insider Own | 6.17% | Shs Outstand | 77.8M | Perf Week | -4.41% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | -5.38% | Insider Trans | 19.3% | Shs Float | 73.0M | Perf Month | -23.28% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.14 | Inst Own | 21.87% | Short Float | 16.6% | Perf Quarter | 5.48% |
| Income | -0.04B | P/S | 136.92 | EPS this Y | 16.31% | Inst Trans | -7.09% | Short Ratio | 17.09 | Perf Half Y | -44.59% |
| Sales | 0.00B | P/B | 2.32 | EPS next 5Y | -8.14% | ROA | -70.84% | Short Interest | 12.12M | Perf YTD | -68.06% |
| Book/sh | 0.39 | P/C | 2.02 | EPS past 3/5Y | 8.24% 8.71% | ROE | -94.08% | 52W High | -72.88% ($3.31) | Perf Year | -60.97% |
| Cash/sh | 0.44 | P/FCF | - | Sales past 3/5Y | 15.39% 10.13% | ROIC | -150.95% | 52W Low | 18.64% ($0.76) | Perf 3Y | -14.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 32.77% | Gross Margin | -75.2% | Volatility(W/M) | 11.8% 7.87% | Perf 5Y | -85.19% |
| Dividend TTM | - | EV/Sales | 70.14 | Sales Y/Y TTM | -6.96% | Oper. Margin | -8320.08% | ATR (14) | 0.08 | Perf 10Y | -99.67% |
| Dividend Ex-Date | - | Quick Ratio | 3.3 | EPS Q/Q | 35.57% | Profit Margin | -7888.98% | RSI (14) | 38.97 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.3 | Sales Q/Q | -14.05% | SMA20 | -9.35% ($0.99) | Beta | 1.53 | Target Price | $5.14 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/11 | SMA50 | -16.92% ($1.08) | Rel Volume | 0.4 | Prev Close | $0.88 |
| Employees | 31 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -17.06% 65.61% | SMA200 | -38.37% ($1.46) | Avg Volume(3M) | 0.71M | Price | $0.9 |
| IPO | 2004/7/27 | Option/Short | Yes/Yes | Trades | 612 | Volume | 282,573 | Change | 2.57% |
A clinical-stage biotech company developing innovative mechanism-based oral anticancer therapies. Through its lead candidate, onvansertib, the company is delivering new treatment options for patients with hard-to-treat metastatic colorectal cancer and a range of other solid tumors.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded less than usual. That is 40% of its average volume.
CRDF has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +16.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $13,692. Peers typically go for $1,089. Compared with its own 1-year average, it is 89% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 21.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #391 of 594 in the industry
Based on market cap of $70M.
CGTX#389 Cognition Therapeutics Inc $71M PER - 
TENX#390 Tenax Therapeutics Inc $70M PER - CRDF#391 Cardiff Oncology Inc $70M PER - 
CSBR#392 Champions Oncology Inc $68M PER - 
SPRO#393 Spero Therapeutics Inc $68M PER 10.7 
FAQ
What kind of company is CRDF?
CRDF belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRDF?
The market cap of CRDF is approximately $70M, ranking 4,692 within its sector.
What is the 52-week high and low for CRDF?
CRDF has recorded a 52-week high of $3.31 and a low of $0.76.
